Roche Building Alternate-Site Diabetes Testing Capability Via Amira
This article was originally published in The Gray Sheet
Executive Summary
Roche Diagnostics will leverage Amira Medical's alternate-site blood glucose testing technology in order to increase its presence in the integrated spot monitoring (ISM) market
You may also be interested in...
Alternate-Site Glucose Test Developers Share Clinical Experience With FDA
TheraSense will present clinical data related to its FreeStyle alternate-site blood glucose monitoring system to FDA's Center for Devices and Radiological Health Oct. 19 to help the agency consider labeling options for such devices.
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.